Fiche publication
Date publication
décembre 2024
Journal
United European gastroenterology journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Magalhaes D, Santiago M, Patita M, Arroja B, Lago P, Rosa I, Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Eugenia C, Sousa P, Portela F, Correia L, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC, Magro F,
Lien Pubmed
Résumé
Predicting the treatment outcomes of biological therapies is an unmet need in Crohn's Disease. In this study, we explored the potential of serum neutrophil-related biomarkers to predict infliximab therapeutic results and disease progression in Crohn's Disease patients, over a 2-year period, in a real-world setting.
Mots clés
Crohn's disease, fecal calprotectin, infliximab, lactoferrin’, lipocalin‐2, neutrophil elastase, resistin, serum neutrophil biomarkers
Référence
United European Gastroenterol J. 2024 12 8;:
